Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment

Executive Summary

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.

You may also be interested in...



England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia

Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.

Smaller EU Countries Call for More Comparative Trials

More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.

Nordic Countries To Agree Closer Collaboration On Joint Price Negotiation and Procurement

Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145594

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel